Organisation paid for research Program year 2025 Source: CMS Open Payments

Adams Clinical LLC

Neither a doctor nor a teaching hospital

Research payments

$12,723,929

199 payments

Through program year 2025, Adams Clinical LLC is reported as receiving $12,723,929 in research payments, across 199 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$40,489	7
2024	Research	$68,611	5
2023	Research	$1,687,881	35
2022	Research	$4,731,903	37
2021	Research	$3,860,802	49
2020	Research	$1,205,463	30
2019	Research	$1,128,780	36

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $6,701,678 38 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $3,798,777 16 payments
Janssen Research & Development, LLC $980,621 23 payments
ACADIA Pharmaceuticals Inc $746,784 36 payments
Sage Therapeutics, Inc. $392,176 66 payments
Sunovion Pharmaceuticals Inc. $103,893 20 payments

Studies the money was for Research payments · program years 2019–2025

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $3,415,966 8 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $2,264,090 5 payments
Assessment of Safety, Tolerability, and Efficacy of Ly3372689 in Early Symptomatic Alzheimer's Disease $1,377,067 4 payments
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression $980,621 23 payments
A Multicenter, Randomized, Flexible-Dose, Double Blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder $959,564 5 payments
Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $638,885 4 payments
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-Avwa in Participants With Early Symptomatic Alzheimer's Disease $511,189 5 payments
Acp-103-059 $471,796 13 payments
A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole $327,631 2 payments
A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $282,077 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.